Published in Aliment Pharmacol Ther on August 17, 2011
Comparison of gastroesophageal reflux disease symptoms and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. J Neurogastroenterol Motil (2013) 0.87
Influence of inhomogeneous static magnetic field-exposure on patients with erosive gastritis: a randomized, self- and placebo-controlled, double-blind, single centre, pilot study. J R Soc Interface (2014) 0.75
The Utility of Endoscopic Biopsies in Patients with Normal Upper Endoscopy. Can J Gastroenterol Hepatol (2016) 0.75
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut (2006) 9.03
Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology (1997) 8.51
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci (1993) 7.98
Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med (1994) 4.76
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med (1998) 4.66
Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA (1998) 4.62
A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med (1993) 4.46
Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med (1991) 4.09
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut (2008) 3.92
Isolation and characterization of adenovirus messenger ribonucleic acid in productive infection. J Virol (1972) 3.83
Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut (2008) 3.81
Selective assay of monomeric and filamentous actin in cell extracts, using inhibition of deoxyribonuclease I. Cell (1978) 3.74
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut (2000) 3.69
Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med (2001) 3.68
An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. CMAJ (2000) 3.45
A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc (1994) 3.14
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol (1998) 3.04
Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol (1999) 3.01
Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology (1996) 3.00
The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut (2012) 2.96
Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol (2000) 2.89
Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. Gut (2008) 2.82
RNA synthesis and processing in adenovirus-infected cells. Cold Spring Harb Symp Quant Biol (1975) 2.82
Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med (1995) 2.78
Risk factors associated with symptoms of gastroesophageal reflux. Am J Med (1999) 2.75
The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther (2013) 2.73
Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol (1996) 2.73
The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med (1995) 2.73
A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med (1989) 2.71
Review article: Associations between Helicobacter pylori and obesity--an ecological study. Aliment Pharmacol Ther (2014) 2.69
Prevalence of Helicobacter pylori in specific forms of gastritis. Further evidence supporting a pathogenic role for H. pylori in chronic nonspecific gastritis. Dig Dis Sci (1991) 2.67
Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation. Aliment Pharmacol Ther (2014) 2.67
Systematic review: gastro-oesophageal reflux disease and dental lesions. Aliment Pharmacol Ther (2008) 2.56
A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N Engl J Med (1998) 2.54
Menetrier's disease: a form of hypertrophic gastropathy or gastritis? Gastroenterology (1993) 2.52
Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med (1994) 2.52
A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct. Endoscopy (1993) 2.49
Isolation of mRNA from KB-cells by affinity chromatography on polyuridylic acid covalently linked to Sepharose. Eur J Biochem (1972) 2.48
Cyclic vomiting syndrome in adults. Neurogastroenterol Motil (2008) 2.40
Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol (1998) 2.38
Functional dyspepsia: the economic impact to patients. Aliment Pharmacol Ther (2013) 2.36
Systemic review: the prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther (2004) 2.35
Cost-effectiveness of cimetidine maintenance therapy in chronic gastric and duodenal ulcer. Gastroenterology (1990) 2.32
Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with oesophageal eosinophilia. Aliment Pharmacol Ther (2014) 2.30
Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther (2003) 2.28
A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol (2000) 2.27
Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl (1998) 2.26
Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol (2001) 2.23
Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology (2001) 2.22
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res (1998) 2.20
Differentiation of functional constipation and constipation predominant irritable bowel syndrome based on Rome III criteria: a population-based study. Aliment Pharmacol Ther (2015) 2.17
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med (1999) 2.15
Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol (2001) 2.12
Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther (2009) 2.11
The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care. Aliment Pharmacol Ther (2014) 2.05
Reorganization of actin in platelets stimulated by thrombin as measured by the DNase I inhibition assay. Proc Natl Acad Sci U S A (1979) 2.02
Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol (1997) 2.02
The association between non-ulcer dyspepsia and other gastrointestinal disorders. Scand J Gastroenterol (1985) 2.01
Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med (1985) 1.98
Predictors of either rapid healing or refractory reflux oesophagitis during treatment with potent acid suppression. Aliment Pharmacol Ther (2014) 1.96
Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol (1998) 1.96
Analysis of clinical specimens by hybridisation with probe containing repetitive DNA from Plasmodium falciparum. A novel approach to malaria diagnosis. Lancet (1984) 1.92
Apoptosis in gastric epithelium induced by Helicobacter pylori infection: implications in gastric carcinogenesis. Am J Gastroenterol (2001) 1.85
Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol (2001) 1.84
Non-cardiac chest pain: prevalence, risk factors, impact and consulting--a population-based study. Aliment Pharmacol Ther (2003) 1.84
Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther (2007) 1.81
Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis (2011) 1.80
On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial. Aliment Pharmacol Ther (1999) 1.80
Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut (2004) 1.76
Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res (2004) 1.76
Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol (2001) 1.75
Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut (1997) 1.75
Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol (1999) 1.74
Identification of the in vitro translation products of adenovirus mRNA by immunoprecipitation. J Virol (1975) 1.74
The effects of lottery incentive and length of questionnaire on health survey response rates: a randomized study. J Clin Epidemiol (1999) 1.73
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther (2005) 1.70
Differences in gastric mechanosensory function after repeated ramp distensions in non-consulters with dyspepsia and healthy controls. Gut (2000) 1.70
Association of anxiety, neuroticism, and depression with dyspepsia of unknown cause. A case-control study. Gastroenterology (1986) 1.69
Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther (2011) 1.68
Development and validation of the Diabetes Bowel Symptom Questionnaire. Aliment Pharmacol Ther (2003) 1.68
Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology (1986) 1.67
Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol (2002) 1.66
Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch Intern Med (1999) 1.64
Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc (2000) 1.64
A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads. Aliment Pharmacol Ther (2014) 1.64
The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther (2004) 1.64
Non-cardiac chest pain: squeezing the life out of the Australian healthcare system? Med J Aust (2000) 1.63
Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology (1984) 1.62
Metal stents for the palliation of inoperable upper gastrointestinal stenoses. Am J Gastroenterol (1998) 1.61
Technology Status Evaluation report. Colonoscopy preparations. May 2001. Gastrointest Endosc (2001) 1.61
Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut (2004) 1.60
Eosinophil infiltration and degranulation in normal human tissue. Anat Rec (1998) 1.59